CONNEQT Health Lodges FDA Pre-Submission for SphygmoCor Cloud in Push toward Software Model

CONNEQT Health (ASX: CQT) has lodged an FDA Pre-Submission package for its SphygmoCor Cloud, marking the company’s first formal step toward seeking US clearance for the product as software as a medical device, or SaMD.

CONNEQT, formerly known as Cardiex, anticipates written FDA feedback in August 2026, is targeting a 510(k) submission in Q2 FY27, and sees potential clearance in Q3 to Q4 FY27.

The move opens a regulatory pathway for a product designed to shift the company's arterial health analytics from dedicated hardware into a cloud software format that could be sold through licensing and subscription models.

If the product is ultimately cleared, the company said SphygmoCor Cloud would become its sixth FDA-cleared product.

What SphygmoCor Cloud Is

SphygmoCor Cloud is described by CONNEQT as a cloud-based SaMD platform built around the company’s arterial health analytics.

In practical terms, the company is trying to move clinically validated analytics that have historically been delivered through dedicated hardware systems into a software environment that can be accessed more flexibly.

CONNEQT said the goal is to simplify deployment and broaden delivery options.

Rather than relying only on hardware-led installations, the cloud model is intended to support software distribution, integration with other devices and broader licensing structures.

Foundational Research

The underlying arterial analysis platform is not new.

The company said its arterial biomarkers are supported by 50 years of foundational research, 24 years of FDA-cleared clinical deployment and thousands of peer-reviewed publications.

SphygmoCor technology is currently used in more than 40 countries.

That context matters because the company is not presenting SphygmoCor Cloud as a new biomarker platform from scratch.

Instead, it is positioning the product as an extension of an established clinical technology base into a different regulatory and commercial format.

This also fits with language CONNEQT has used in earlier filings around moving the broader business toward subscription, usage-based and data-driven revenue streams.

Previous updates referred to concepts such as Arterial Intelligence and Biomarker-as-a-Service, with management describing a wider effort to build recurring software-style revenue layers around its cardiovascular monitoring assets.

Regulatory and Commercial Detail

The commercial appeal of SphygmoCor Cloud, based on the company’s description, lies in the fact that software can potentially be distributed in ways that hardware cannot.

CONNEQT said that, if cleared, the product could support several models including Biomarker-as-a-Service (BaaS), third-party device integration via APIs, enterprise and population health licensing, and potential consumer or direct-to-patient channels.

Those options suggest management is aiming to expand beyond one-off hardware sales toward licensing and subscription arrangements.

The announcement did not disclose a trial budget, engineering cost or stand-alone funding requirement for taking the product from pre-submission through to a full FDA filing.

That funding question sits in a live corporate context.

On 19 June 2026, CONNEQT completed a A$5.5 million two-tranche placement at A$0.022 a share and proposed a non-underwritten share purchase plan of up to about A$0.5 million.

The company did not specifically allocate those funds to SphygmoCor Cloud, but the raise provides near-term capital support as the FDA process moves forward.

What to Watch Next

The most immediate milestone is the FDA’s written response, which management expects in August 2026.

That feedback should provide a clearer sense of whether the agency is aligned with the proposed 510(k) route and whether it requires additional information before a full submission.

Between now and then, the market is likely to look for signs that CONNEQT can complete the technical, regulatory, and product work needed to convert the pre-submission into a formal filing.

Commercial execution is the other major watchpoint. Even if FDA clearance is eventually secured, the company’s strategy still depends on whether enterprise customers, platform partners or other channels adopt the software format in a way that supports the shift away from hardware-led distribution.

FDA Step, Long Runway

CONNEQT’s FDA pre-submission for SphygmoCor Cloud is a meaningful strategic milestone because it starts the formal US regulatory path for a product designed to move the company’s arterial analytics into a cloud software model.

But the announcement is still an early-stage regulatory update: clearance is not expected before FY27 at the earliest based on management’s timetable, and the outcome remains tied to FDA feedback, capital resources and the company’s ability to commercialise the software format after approval.

For now, today’s announcement gives investors a defined regulatory starting point and an indicative timetable. What it does not yet provide is proof of clearance, a funded end-to-end regulatory budget, or evidence that the cloud format has already translated into contracted demand.